Lämmle B, Bounameaux H, Marbet G A, Eichlisberger R, Duckert F
Thromb Haemost. 1980 Dec 19;44(3):150-3.
The validity of the amidolytic Factor X assay for the control of long term oral anticoagulation (OA) was investigated in 42 patients randomized into 2 groups; PT group (anticoagulant dosage according to PT) and F.X group (anticoagulant dosage based on F.X). An independent expert's dosage according to F.X served for analysis in the former group. In the F.X group the F.X based dosage was considered valid only when not differing by more than 15% from the expert's PT based dosage. Confirming the good correlation between PT and F.X the study further demonstrates that the changes from one control to the next one, delta PT and delta F.X, too, are significantly correlated (r = 0.58, p less than 0.001, n = 217). In over one third of the periods the dosage proposals based on PT and F.X were identical and differed by more than 15% in only 12/217 instances. Our results justify a large trial on the control of OA by the amidolytic F.X assay.
在42例患者中研究了用于长期口服抗凝治疗(OA)控制的酰胺分解法X因子检测的有效性,这些患者被随机分为两组:PT组(根据PT调整抗凝剂剂量)和F.X组(根据F.X调整抗凝剂剂量)。在前一组中,采用由独立专家根据F.X给出的剂量进行分析。在F.X组中,只有当基于F.X的剂量与基于专家PT的剂量相差不超过15%时,才认为基于F.X的剂量是有效的。该研究证实了PT与F.X之间存在良好的相关性,进一步表明从一次检测到下一次检测的变化,即ΔPT和ΔF.X,也具有显著相关性(r = 0.58,p < 0.001,n = 217)。在超过三分之一的时间段内,基于PT和F.X的剂量建议是相同的,仅在12/217例中相差超过15%。我们的结果为通过酰胺分解法F.X检测控制OA的大型试验提供了依据。